Johnson & Johnson’s venture arm, J&J Innovation, just led a $24 million Series C round into First Aid Shot Therapy – a consumer-facing startup that purveys over-the-counter “liquid shots” that treat pain, hangovers, heartburn and colds.
In terms of product packaging and demographic, it fits solidly with the Five Hour Energy cocktails of the world. The idea to use a shot is to get the product in the bloodstream, faster.
FAST Liquid Relief products can be found in a number of grocery stores around the country, and the C round will help expand into more. The company was notably launched by Jay Pasricha, a neurogastroenterology professor at John Hopkins University.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The berry-flavored pain relief shot contains choline salicylate, an NSAID that’s similar to aspirin but faster-acting, and caffeine. The hangover shot contains the same ingredients, but with a citrus taste. Colds are treated with a commonly used cough suppressant, dextromethorphan hydrobromide and the decongestant phenylephrine. Tastes like elderberries and menthol, which works as an analgesic. The heartburn relief shot is, in essence, liquid Tums.
JJDC typically invests in biopharma, medical devices and diagnostics – but also makes investments in consumer products. Other investors include Lumira Capital, Sofinnova Ventures, Redmile Group and HealthQuest Capital.